All In Biotech

Drug Trial Radar · NCT00792298

Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)

A Phase IIb, Multicenter, Randomized, Double-Blind Placebo-Controlled, 2-period Adaptive Crossover Polysomnography Study to Evaluate Safety and Efficacy of MK-4305 in Patients With Primary Insomnia

Last checked: Nov 19, 2026Latest source record: Nov 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 254 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

254

Actual

Start

Nov 5, 2008

Primary completion

Dec 26, 2009

Study completion Dec 26, 2009

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Nov 17, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A cross-over, polysomnography study to test the safety, tolerability and effectiveness of different doses of suvorexant (MK-4305) in the treatment of patients with primary insomnia.

Conditions

  • Primary Insomnia

Interventions

  • SuvorexantDrug

    oral tablet taken before bedtime

  • Dose-matched Placebo to SuvorexantDrug

    Dose-matched placebo to suvorexant taken before bedtime (oral tablet)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. LS Mean Sleep Efficiency (SE) During Periods 1 and 2Time frame: Night 1 and end of Week 4

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.